- Company name
- Charles River Laboratories
- Sector
- Life science research models and drug safety testing
- About
- Charles River Laboratories International, Inc. (Charles River) is based in Wilmington, Massachusetts. It helps biopharmaceutical companies discover and develop medicines. It has three segments: Discovery and Safety Assessment, which does regulated preclinical safety studies, Manufacturing Solutions, which tests biologics and the microbial quality of products, and Research Models and Services, which supplies research models. Revenue was $982.7 million in Q3 2026 and $2,982.6 million for nine months. The common stock trades on the NYSE in US dollars. Charles River files 10-K and 10-Q reports.
- Thesis
- The price of Charles River depends on whether demand from biopharmaceutical clients for preclinical safety studies keeps its recovery, and whether the company reaches its margin targets. In Q3 2026 organic revenue grew 4.7%, the non-GAAP operating margin rose to 23.0% and non-GAAP earnings per share rose 27.2% to $3.09. Charles River raised its 2026 guidance to non-GAAP earnings per share of $11.35 to $11.55, and at its Investor Day in September 2026 it set targets for 2027 to 2030 of organic revenue growth of 5% to 7% a year and a non-GAAP operating margin of about 24% in 2030. For the price to hold or rise, four things must be true. Net bookings for safety studies must keep growing. The supply of research models, including non-human primates from its new Cambodian supplier, must stay stable. Clients must not move to other test methods faster than Charles River can offer them. The purchase of the bioanalysis and DMPK businesses of Frontage must close in the first half of 2027 as planned. The Q4 2026 report, expected in February 2027, with its 2027 guidance, is the next test.
- Risks
- Demand depends on the research spending of biopharmaceutical clients and on biotech funding. Organic revenue of Research Models and Services fell 0.6% in Q3 2026.
The supply of non-human primates is a legal and operational risk. A securities class action and a derivative lawsuit about past disclosures on the import of non-human primates are still open.
Debt rose. Total debt and finance leases were $2,456.5 million at September 26, 2026, against $2,152.2 million at the end of 2025, and the Frontage purchase adds about $470 million of cash needs.
Clients can use more test methods without animals. Charles River invests in these methods through its Alternative Methods Advancement Project, but a fast change could lower demand for research models and studies.
Divestitures leave obligations. Charles River may fund up to $45.0 million of future EBITDA losses of the CDMO and Cell Solutions businesses that it sold.
- Balance sheet
- Cash: $200M
Debt: $2.4B
Net debt: $2.2B
Undrawn credit line: $1.1B, to December 2029
Debt due within 12 months: $3.0M
Last debt due: 2031
At September 26, 2026, Charles River had total debt and finance leases of $2,456.5 million: $943.2 million on its $2.0 billion revolving credit facility, which matures in December 2029, $500.0 million of 4.25% senior notes due 2028, $500.0 million of 3.75% senior notes due 2029, $500.0 million of 4.00% senior notes due 2031, other debt of $3.7 million and finance leases of $9.7 million. Cash and cash equivalents were $200.4 million. Operating cash flow was $474.9 million for nine months. Charles River repurchased 1.7 million shares for $300.0 million in the first nine months of 2026, and $700.0 million of the repurchase program remained. Operating lease liabilities are not in these figures.
As of Sep 26, 2026.
- Checkpoints
- Feb 17, 2027 (estimate): Q4 2026 results and 2027 guidance. Pending. Watch: Non-GAAP earnings per share for 2026 are in the guided range of $11.35 to $11.55 and the 2027 guidance shows organic revenue growth, and this passes; a result below the range or guidance for lower revenue fails.
Q2 2027 (estimate): Frontage purchase closes. Pending. Watch: The purchase of the bioanalysis and DMPK businesses of Frontage closes by the end of June 2027, and this passes; a delay past June 2027 or an end to the agreement fails.
- Recent events
- Nov 9, 2026: Charles River agreed to buy the bioanalysis and DMPK businesses of Frontage Holdings in Exton, Pennsylvania for about $470 million in cash, plus payments of up to $75 million that depend on their results. It expects the deal to close in the first half of 2027 and to be neutral to non-GAAP earnings per share in 2027.
Nov 4, 2026: Charles River reported Q3 2026 results. Revenue fell 2.2% to $982.7 million because of divestitures, and organic revenue rose 4.7%. GAAP earnings per share were $6.86, including a benefit of $5.06 per share from the reversal of acquired tax reserves, and non-GAAP earnings per share were $3.09. It raised its 2026 guidance.
Sep 24, 2026: At its Investor Day, Charles River presented its Pathway to Purpose strategy and targets for 2027 to 2030: organic revenue growth of 5% to 7% a year, a non-GAAP operating margin of about 24% and growth of non-GAAP earnings per share at a low-double-digit rate a year.
May 22, 2026: Charles River sold certain European Discovery Services businesses to IQVIA for $126.4 million in cash.
May 6, 2026: Charles River sold its CDMO and Cell Solutions businesses to GI Partners. It paid net cash of $12.4 million to the buyer and may fund up to $45.0 million of future EBITDA losses of these businesses.
Jan 14, 2026: Charles River bought certain assets of a supplier of non-human primates in Cambodia for a preliminary price of $507.3 million, of which $335.0 million was paid at closing.